中华实验和临床感染病杂志（电子版）
中華實驗和臨床感染病雜誌（電子版）
중화실험화림상감염병잡지（전자판）
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL INFECTIOUS DISEASES(ELECTRONIC VERSION)
2015年
4期
490-493
,共4页
高学松%高丽丽%芦红萍%刘顺爱%曹金凤%段雪飞%成军
高學鬆%高麗麗%蘆紅萍%劉順愛%曹金鳳%段雪飛%成軍
고학송%고려려%호홍평%류순애%조금봉%단설비%성군
肝炎,乙型%复方甘草酸苷%单核细胞趋化蛋白2%上皮来源的中性粒细胞活化肽-78
肝炎,乙型%複方甘草痠苷%單覈細胞趨化蛋白2%上皮來源的中性粒細胞活化肽-78
간염,을형%복방감초산감%단핵세포추화단백2%상피래원적중성립세포활화태-78
Hepatitis B%Compound glycyrrhizin%Monocyte chemoattractant protein 2%Epithelial cell-derived neutrophil-activating peptide-78
目的：研究复方甘草酸苷改善慢性乙型肝炎患者肝脏炎症的机制。方法将21例慢性乙型肝炎患者分为试验组（10例）与对照组（11例），试验组患者给予复方甘草酸苷200 mg入液静脉输注，同时给予苦参素注射液、还原型谷胱甘肽和多烯磷脂酰胆碱注射液保肝，恩替卡韦抗病毒治疗；对照组患者除不使用复方甘草酸苷外与治疗组治疗相同，疗程均为2周。分别在治疗前后检测患者肝功能指标及多个细胞因子水平。结果两组患者肝功能均有好转，试验组ALT水平[（103.4±80.4）U/L]下降显著（t =6.162，P =0.000）；MCP-2治疗后[（40.25±14.51）pg/ml]较治疗前显著下降（t =2.381，P=0.041）；ENA-78治疗后较治疗前升高（t=－3.561，P=0.006）。试验组和对照组IL-16、6Ckine、TPO、SCF、TSLP、IL-33、IL-20、IL-21、IL-23、IL-28α、TRAIL和SDF-1α+β治疗前后差异均无统计学意义。试验组和对照组IL-18治疗前后均有所下降。结论复方甘草酸苷可显著改善肝脏炎症，抗炎的机制可能与抑制炎症因子MCP-2，活化ENA-78有关。
目的：研究複方甘草痠苷改善慢性乙型肝炎患者肝髒炎癥的機製。方法將21例慢性乙型肝炎患者分為試驗組（10例）與對照組（11例），試驗組患者給予複方甘草痠苷200 mg入液靜脈輸註，同時給予苦參素註射液、還原型穀胱甘肽和多烯燐脂酰膽堿註射液保肝，恩替卡韋抗病毒治療；對照組患者除不使用複方甘草痠苷外與治療組治療相同，療程均為2週。分彆在治療前後檢測患者肝功能指標及多箇細胞因子水平。結果兩組患者肝功能均有好轉，試驗組ALT水平[（103.4±80.4）U/L]下降顯著（t =6.162，P =0.000）；MCP-2治療後[（40.25±14.51）pg/ml]較治療前顯著下降（t =2.381，P=0.041）；ENA-78治療後較治療前升高（t=－3.561，P=0.006）。試驗組和對照組IL-16、6Ckine、TPO、SCF、TSLP、IL-33、IL-20、IL-21、IL-23、IL-28α、TRAIL和SDF-1α+β治療前後差異均無統計學意義。試驗組和對照組IL-18治療前後均有所下降。結論複方甘草痠苷可顯著改善肝髒炎癥，抗炎的機製可能與抑製炎癥因子MCP-2，活化ENA-78有關。
목적：연구복방감초산감개선만성을형간염환자간장염증적궤제。방법장21례만성을형간염환자분위시험조（10례）여대조조（11례），시험조환자급여복방감초산감200 mg입액정맥수주，동시급여고삼소주사액、환원형곡광감태화다희린지선담감주사액보간，은체잡위항병독치료；대조조환자제불사용복방감초산감외여치료조치료상동，료정균위2주。분별재치료전후검측환자간공능지표급다개세포인자수평。결과량조환자간공능균유호전，시험조ALT수평[（103.4±80.4）U/L]하강현저（t =6.162，P =0.000）；MCP-2치료후[（40.25±14.51）pg/ml]교치료전현저하강（t =2.381，P=0.041）；ENA-78치료후교치료전승고（t=－3.561，P=0.006）。시험조화대조조IL-16、6Ckine、TPO、SCF、TSLP、IL-33、IL-20、IL-21、IL-23、IL-28α、TRAIL화SDF-1α+β치료전후차이균무통계학의의。시험조화대조조IL-18치료전후균유소하강。결론복방감초산감가현저개선간장염증，항염적궤제가능여억제염증인자MCP-2，활화ENA-78유관。
Objective To study the mechanism of reduction inflammation of the liver in chronic hepatitis B patients treatment with compound glycyrrhizin. Methods Total of 21 patients with chronic hepatitis B were divided into treatment group (10 cases) and control group (11 cases). Patients in both groups were given entecavir tablets 0.5 mg once a day, combined with the regular liver protecting therapy, including matrine injection, reduced glutathione for injection and polyene phosphatidylcholine injection. Patients in treatment group were given compound glycyrrhizin solution at dose of 200 mg by intravenous infusion. Patients in both groups were treated for 2 weeks. The liver function and level of multiple cytokines of patients were tested before and after treatment, respectively. Results The liver function of the patients in two groups were signiifcantly improved. ALT levels [(103.4 ± 80.4) U/L] decreased signiifcantly in the treatment group (t=6.162, P=0.000);MCP-2 signiifcantly decreased after treatment [(40.25 ± 14.51) pg/ml] (t=2.381, P=0.041);ENA-78 also signiifcantly increased (t=-3.561, P=0.006). No signiifcant differences were found in the change of IL-16, 6Ckine, TPO, SCF, TSLP, IL-33, IL-20, IL-21, IL-23, IL-28α, TRAIL and SDF-1α+βin the two groups. The levels of IL-18 were decreased in two groups after treatment. Conclusions The liver inlfammation could be reduced by compound glycyrrhizin signiifcantly. The mechanism may be related with the suppression of MCP-2 or activation of ENA-78.
